Cargando…

A covalent BTK ternary complex compatible with targeted protein degradation

Targeted protein degradation using heterobifunctional chimeras holds the potential to expand target space and grow the druggable proteome. Most acutely, this provides an opportunity to target proteins that lack enzymatic activity or have otherwise proven intractable to small molecule inhibition. Lim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schiemer, James, Maxwell, Andrew, Horst, Reto, Liu, Shenping, Uccello, Daniel P., Borzilleri, Kris, Rajamohan, Nisha, Brown, Matthew F., Calabrese, Matthew F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981747/ https://www.ncbi.nlm.nih.gov/pubmed/36864023 http://dx.doi.org/10.1038/s41467-023-36738-z

Ejemplares similares

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
por: Zain, Rula, et al.
Publicado: (2021)

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
por: Wu, Hong, et al.
Publicado: (2014)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
por: Lewis, Katharine L, et al.
Publicado: (2021)

Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK
por: Forster, Michael, et al.
Publicado: (2020)

Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function
por: Trory, Justin S., et al.
Publicado: (2022)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells
por: Logie, Emilie, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
por: Ringheim, Garth E., et al.
Publicado: (2021)

Novel non-covalent stable supramolecular ternary system comprising of cyclodextrin and branched polyethylenimine
por: Kasprzak, Artur, et al.
Publicado: (2016)

Modeling the Effect of Cooperativity in Ternary Complex Formation and Targeted Protein Degradation Mediated by Heterobifunctional Degraders
por: Park, Daniel, et al.
Publicado: (2022)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Super Toughened Poly(lactic acid)-Based Ternary Blends via Enhancing Interfacial Compatibility
por: Wu, Feng, et al.
Publicado: (2019)

A highly soluble, crystalline covalent organic framework compatible with device implementation
por: Wang, Lingling, et al.
Publicado: (2018)

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
por: Linton, Kim, et al.
Publicado: (2023)

P1219: BGB-16673, A BTK DEGRADER, OVERCOMES ON-TARGET RESISTANCE FROM BTK INHIBITORS AND PRESENTS SUSTAINABLE LONG-TERM TUMOR REGRESSION IN LYMPHOMA XENOGRAFT MODELS
por: Wang, Haitao, et al.
Publicado: (2023)

P1247: GB5121 IS A NOVEL, IRREVERSIBLE, COVALENT BTK INHIBITOR WITH HIGH SELECTIVITY AND CNS-PENETRANCE FOR TREATMENT OF CNS MALIGNANCIES
por: Yusuf, I., et al.
Publicado: (2022)

PB2205: A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL-895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS
por: Macwan, Joyce, et al.
Publicado: (2023)

Adsorption Behavior of a Ternary Covalent Organic Polymer Anchored with SO(3)H for Ciprofloxacin
por: Wang, Zhuoran, et al.
Publicado: (2023)

Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation
por: Wurz, Ryan P., et al.
Publicado: (2023)

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Scarfò, Lydia, et al.
Publicado: (2023)

Circulating versus cellular tumor DNA for the detection of BTK resistant CLL clones
por: Trummer, Arne, et al.
Publicado: (2022)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate
por: Roy, Michael J., et al.
Publicado: (2019)

Enhanced Photocatalytic Degradation of Ternary Dyes by Copper Sulfide Nanoparticles
por: Ajibade, Peter A., et al.
Publicado: (2021)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Comment on a suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands
por: Douglass, Eugene F., et al.
Publicado: (2021)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study
por: Hess, Lisa M., et al.
Publicado: (2022)

Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders
por: Hughes, Scott J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2npg9eccbntifah36e223huq3c